2 Top Growth Stocks to Buy Right Now Without Hesitation

The article highlights MercadoLibre’s heavy reinvestment in logistics and free-shipping infrastructure to defend its Latin American e-commerce and fintech leadership, while also noting Eli Lilly’s GLP-1-driven growth and $82B-$85B full-year revenue outlook. Lilly is expanding capacity with another $4.5B investment in its Indiana manufacturing facility and reported positive phase 3 retatrutide results, reinforcing its growth pipeline. Rising 10-year Treasury yields are cited as a headwind for valuation, but the piece is primarily a bullish long-term growth-stock recommendation rather than new market-moving news.

Analysis

The market is treating MELI like a pure growth multiple story, but the more important takeaway is that its reinvestment intensity is becoming a moat-expansion phase rather than a margin problem. Heavy logistics capex in Latin America should pressure near-term FCF, yet it also raises switching costs for merchants and consumers simultaneously, which is harder to replicate than ad spend or discounting. If execution holds, the next leg of value creation is likely to come from financing and payments attach rates, not just marketplace GMV.

Competitive pressure is the key second-order issue. Amazon, Shein, and Temu can subsidize acquisition, but they do not automatically solve last-mile reliability, cross-border delivery friction, or local credit underwriting; that means the fight is less about price and more about who can subsidize the ecosystem longest. The underappreciated risk is that a stronger dollar / higher local rates environment can make consumer credit more fragile, which would hit both MELI’s fintech book and discretionary basket mix with a lag of 1-3 quarters.

On LLY, the core debate is no longer demand creation; it is capacity allocation and payer normalization. Once a category becomes a daily behavior rather than a novelty, the marginal upside comes from broader reimbursement, earlier-line usage, and adjacent indications, while the downside is that any evidence of slower persistence or reimbursement pushback can compress the multiple quickly because expectations are already anchored to perfection. The market may be underestimating how much manufacturing scale and channel access become strategic assets in GLP-1, especially versus peers still constrained by supply.

Key Decisions for Investors

• Go long MELI on 3-6 month horizon, preferably on pullbacks: the setup favors a capex-driven moat expansion trade; target 15-20% upside if market rewards logistics share gains, with 10-12% downside if reinvestment disappoints.
• Pair trade: long MELI / short PDD for 1-2 quarters to express local-moat versus cross-border price competition; use a 1:1 notional with stop if Latin America consumer data weakens materially.
• Trim or hedge LLY into strength with covered calls over 30-60 days: upside is still positive, but the risk/reward is less attractive after a multi-year rerating; consider selling 5-10% OTM calls to finance downside protection.
• For a relative-value healthcare expression, pair long LLY / short NVO on 3-6 months only if you want to bet on execution and manufacturing scale; the spread should benefit if U.S. reimbursement and supply expansion continue.
• Avoid chasing AMZN on this news; if anything, use it as a hedge against MELI in a basket short, since Amazon remains the most plausible external pressure point on Latin American e-commerce margins.